Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)

PacBio Q2 revenue fell to $39.0 million, net loss widened, and a new CEO was named

Negative Impact 4 of 5 earnings Written later

PacBio reported second-quarter 2026 revenue of $39.0 million, down from $39.8 million a year earlier, and a GAAP net loss of $44.7 million, up from $41.9 million. The company also named Mark Van Oene as President and CEO effective August 5, 2026, succeeding Christian Henry, and approved a restructuring that cuts about 8% of its workforce and is expected to lower annualized operating expenses by $30 million to $40 million by the end of 2027.

Key points

  • Q2 2026 revenue of $39.0 million vs. $39.8 million in Q2 2025; GAAP net loss of $44.7 million vs. $41.9 million
  • Full-year 2026 revenue outlook of $155 million to $165 million
  • Mark Van Oene became CEO effective August 5, 2026; Christian Henry stepped down and will remain on the Board
  • Restructuring: about 40 employees (about 8% of workforce) and about $2.0 million in pre-tax charges, expected in Q3 2026

The filing

CompanyPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:23 PM ET
Accession number0001299130-26-000117

Items reported: 2.02 Results of Operations2.05 Exit / Restructuring Costs5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.